Thermo Fisher Scientific Inc. $TMO Shares Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3,023.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,000 shares of the medical research company’s stock after purchasing an additional 164,557 shares during the period. Thermo Fisher Scientific accounts for about 0.9% of International Assets Investment Management LLC’s portfolio, making the stock its 19th largest position. International Assets Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $114,758,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Bank OZK purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $1,096,000. Ausdal Financial Partners Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth $456,000. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $15,501,867,000. German American Bancorp Inc. purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at about $4,920,000. Finally, Parallax Volatility Advisers L.P. purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at about $814,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $696.78 on Friday. The firm’s fifty day moving average is $654.87 and its two-hundred day moving average is $552.94. The firm has a market cap of $257.63 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.89 and a beta of 0.87. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The business had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $5.79 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.24 EPS for the current year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 2,831 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the transaction, the vice president directly owned 11,560 shares of the company’s stock, valued at approximately $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 76,199 shares of company stock valued at $45,896,780 in the last three months. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research reports. DZ Bank lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Friday, October 23rd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. UBS Group reiterated a “buy” rating and issued a $800.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, October 22nd. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating for the company. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $689.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.